Jump to Navigation


The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.


  • Recent News
  • Investor Contact
Sep 20, 2016

Aethlon Medical, Inc. (Nasdaq: AEMD), today announced changes to its corporate presentation schedule over the coming month. On September 6th, the Company disclosed that its Chairman and CEO, Jim...

Sep 12, 2016

Aethlon Medical, Inc. (Nasdaq: AEMD), announced today that Jim Joyce, Chairman and CEO, and Jim Frakes, Chief Financial Officer, will be presenting at the Rodman & Renshaw 18th Annual Global...

Sep 9, 2016

Aethlon Medical, Inc. (Nasdaq: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. After a seven-week vacation, the U.S. Congress and Senate returned to work on...

Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc

print email

Back to Top

Site 'Subpage' Navigation:

Investor Relations


Back to Top